# What Is the Status of the TAME Metformin Trial in 2026

The Targeting Aging with Metformin (TAME) trial is technically registered as ongoing in 2026 but has not enrolled a single participant, remaining stalled due to a persistent lack of commercial funding for the off-patent drug. In its wake, the U.S. government has launched the $38 million VITAL-H trial to test alternative FDA-approved drugs like rapamycin and semaglutide, while new clinical data revealing that metformin blunts the cardiovascular benefits of exercise has prompted a shift toward more personalized longevity interventions.

## The Promise of Targeting Aging Itself

For decades, the global medical establishment has treated the diseases of aging—such as cancer, Alzheimer's, heart disease, and osteoarthritis—as distinct, isolated conditions. This traditional approach to healthcare has successfully extended the average human lifespan, which is projected to reach a global average of 72.3 years by 2050 [cite: 1]. However, it has largely failed to extend *healthspan*, defined as the number of years a person lives in good health and free of chronic disability. Currently, men spend an average of 8.3 years and women 11 years at the end of their lives in poor health [cite: 2]. With an estimated 2.1 billion people expected to be over the age of 60 by 2050, 80% of whom will live in low- and middle-income countries, the socio-economic burden of age-related disease is becoming unsustainable [cite: 1].

In the early 2010s, researchers in the emerging field of geroscience proposed a radical paradigm shift: instead of waiting for diseases to manifest, what if we targeted the underlying biological mechanisms of aging directly? The "geroscience hypothesis" posits that the biological processes of aging are the greatest risk factors for chronic diseases and disabilities [cite: 3]. By slowing the fundamental biological clock—targeting hallmarks like mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, and epigenetic alterations—scientists hypothesized they could delay the onset of all age-related chronic diseases simultaneously [cite: 4].

### The Origins and Architecture of the TAME Trial

To prove this hypothesis in humans, Dr. Nir Barzilai and his colleagues at the Albert Einstein College of Medicine, backed by the American Federation for Aging Research (AFAR), designed the Targeting Aging with Metformin (TAME) trial [cite: 3, 5]. 

The trial's design is highly ambitious and was intended to serve as a template for future aging intervention studies [cite: 5, 6]. The protocol calls for enrolling over 3,000 generally healthy, non-diabetic adults between the ages of 65 and 79 across 14 leading U.S. research institutions, with Wake Forest University School of Medicine serving as the coordinating center [cite: 5]. Over a period of six years, half of the participants would receive metformin, and the other half would receive a placebo [cite: 7]. 

However, the true brilliance of TAME lies not necessarily in the specific drug being tested, but in its regulatory strategy. The U.S. Food and Drug Administration (FDA) currently only approves drugs for conventionally designated diseases. Because the FDA does not recognize "aging" itself as a disease, no pharmaceutical company can legally develop or market a drug to treat it [cite: 3, 7]. To overcome this regulatory deadlock, the TAME investigators worked directly with the FDA in 2015 to create a composite primary endpoint [cite: 8]. Instead of attempting to measure an abstract "biological age," the trial measures the time-to-first occurrence of any major age-related event, including heart disease, cancer, dementia, stroke, and mortality [cite: 8]. 

If metformin can delay the clustering of these diseases, it would provide clinical proof-of-concept that aging is a treatable condition. Earning this "indication" from the FDA would effectively legitimize aging as a target for pharmaceutical intervention, creating a regulatory pathway for a massive new industry of gerotherapeutics [cite: 3, 5].

### Why Metformin Was Chosen

Metformin, a first-line oral medication used to treat type 2 diabetes, was selected as the vanguard drug for this trial for several compelling reasons. First, it has an unparalleled safety record. It has been prescribed to millions of people for over 60 years and is generally well-tolerated, making it ethically viable to test in healthy, non-diabetic older adults [cite: 3, 5]. 

Second, extensive preclinical and observational data suggest it targets several recognized "hallmarks of aging." At a cellular level, metformin reduces glucose production in the liver (gluconeogenesis) and improves insulin sensitivity in peripheral tissues [cite: 9, 10]. Crucially, it activates AMP-activated protein kinase (AMPK), an enzyme that plays a critical role in cellular energy homeostasis, while simultaneously inhibiting the mechanistic target of rapamycin (mTOR) pathway [cite: 4, 11]. By modulating these nutrient-sensing pathways, metformin reduces oxidative stress, limits systemic inflammation, and stimulates autophagy—the process by which cells clear out damaged components [cite: 4, 10]. 

Furthermore, observational data from diabetic populations taking metformin has frequently shown lower incidences of certain cancers and cardiovascular events compared to diabetics on other regimens [cite: 10]. Some epidemiological evidence even suggested that diabetic patients on metformin could outlive matched non-diabetic controls, prompting researchers to question its utility as a broad anti-aging agent [cite: 10, 12].

Because of its well-documented safety, low cost, and multi-pathway biological activity, the NIH-funded Geroscience Network recommended metformin as the ideal candidate to test the geroscience hypothesis in humans [cite: 5].

## The Funding Paradox: Why TAME Is Stalled in 2026

A timeline of TAME’s history reveals a decade in limbo. Despite securing FDA agreement on a revolutionary composite endpoint in 2015, the trial has remained stalled through mid-2026, largely due to a lack of commercial incentive for the off-patent drug. A search of the modernized ClinicalTrials.gov database confirms the trial (NCT04370067) remains in a holding pattern, technically listed as "ongoing" but awaiting recruitment [cite: 6, 13].

### The Curse of the Off-Patent Drug

The barrier to launching TAME is entirely financial, rooted in the economics of the pharmaceutical industry. The trial requires approximately $50 million to execute [cite: 8]. In the traditional biotech ecosystem, $50 million for a massive Phase 3 clinical trial is a relatively modest sum. However, metformin is a generic drug that costs mere pennies per pill [cite: 8]. 

Because no pharmaceutical company holds a patent on metformin, no corporation stands to profit from proving it extends healthspan. Even if TAME succeeds brilliantly, a company cannot monopolize the sale of metformin for aging. Without the promise of a return on investment, private venture capital will not fund the trial [cite: 8]. This generic drug paradox has left TAME entirely dependent on public funding and philanthropic donations.

The National Institute on Aging (NIA) contributed roughly $5 to $9 million, which was highly useful for preliminary study design and biomarker development, but fell far short of the operational costs required for a 3,000-person, six-year trial [cite: 8]. Over the last decade, the trial has suffered a frustrating series of near-misses with wealthy philanthropists, partial foundation commitments, and unfulfilled promises from tech entrepreneurs, none of which fully closed the funding gap [cite: 8].

### Advocacy and the Longevity Logjam

By 2026, the inability to fund TAME has become a flashpoint for frustration within the scientific and advocacy communities. While an estimated $13 billion flowed into private longevity startups developing patented therapies between 2013 and 2026, the single trial designed to clear the regulatory path for all of them was left starved for capital [cite: 8].

This frustration culminated in organized global action. In April 2026, longevity advocates, scientists, and members of the Effective Altruism community held rallies in cities ranging from London and Paris to San Francisco and Tel Aviv [cite: 8]. Their core message highlighted the massive opportunity cost of delayed research, arguing that treating aging as a public good is a highly tractable intervention. Advocates noted that every day of delay in longevity research translates to roughly 100,000 lives lost globally to age-related decline, and that relying on market self-interest to fund generic public-health trials is a failing strategy [cite: 8].

### The Rise of Mega-Philanthropy: The Hevolution Foundation

While traditional venture capital has ignored TAME, the philanthropic landscape has evolved dramatically. The most notable new player is the Riyadh-based Hevolution Foundation. Founded to shift the global healthcare paradigm from disease treatment to prevention, Hevolution has committed over $400 million to healthspan sciences within a 21-month period ending in 2024, positioning itself as the world's largest philanthropic funder of geroscience [cite: 2]. 

Hevolution has aggressively funded academic research, awarding massive long-term grants such as $20.2 million to Albert Einstein College of Medicine (focused on cellular senescence) and $32.3 million to Northwestern University (focused on proteostasis) [cite: 2]. The foundation also launched international grant programs, including the Hevolution Foundation Geroscience Research Opportunities (HF-GRO) providing up to $25 million in 2024, and the Longevity Impetus Grants program—co-funded with the Rosenkranz Foundation—which provides awards of up to $500,000 with rapid three-week funding decisions to cut through bureaucratic red tape [cite: 2, 14].

Furthermore, Hevolution partnered with XPRIZE to launch the $101 million XPRIZE Healthspan competition, challenging teams to develop therapeutics that restore muscle, cognitive, and immune function by a decade or more [cite: 15]. By May 2025, the competition narrowed its field to 40 teams, with 10 finalists slated to receive $1 million each in 2026 to move into human trials [cite: 15]. 

Despite this massive influx of philanthropic capital into the broader geroscience ecosystem, TAME's specific operational funding gap remains unresolved as of mid-2026, leaving the trial's physical launch in a state of suspended animation [cite: 8].

## The Metformin and Exercise Paradox (The Rutgers Study)

Even if the funding for TAME were to magically appear tomorrow, the scientific consensus around metformin as a flawless, universal anti-aging intervention has begun to fracture. In late 2025, a critical study published in *The Journal of Clinical Endocrinology & Metabolism* by a team from Rutgers University introduced a massive complication into the longevity narrative [cite: 16, 17].

### Blunting the Benefits of Physical Activity

For nearly two decades, standard medical guidance suggested that patients with elevated blood sugar or those at risk for metabolic syndrome should combine metformin with regular physical exercise, assuming the two proven interventions would stack synergistically [cite: 16, 17, 18]. As Rutgers lead author Dr. Steven Malin noted, "Most health care providers assume one plus one equals two. The problem is that most evidence shows metformin blunts exercise benefits" [cite: 18].

To test this rigorously, the Rutgers team conducted a 16-week double-blind, placebo-controlled trial. They enrolled 72 adults at risk for metabolic syndrome and divided them into four cohorts: high-intensity exercise with placebo, high-intensity exercise with metformin, low-intensity exercise with placebo, and low-intensity exercise with metformin [cite: 18, 19]. 

The results were highly concerning for the preventive longevity community. The researchers found that metformin actively *blunted* several critical physiological improvements normally gained from physical training [cite: 20]. 

Specifically, the study measured vascular insulin sensitivity—the ability of blood vessels to dilate and deliver oxygen, hormones, and nutrients to tissues after a meal [cite: 18]. Exercise alone dramatically improved this function, allowing muscles to effectively shuttle glucose out of the bloodstream. However, when metformin was added to the exercise regimen, these improvements shrank significantly at the level of both large conduit arteries and tiny capillaries, regardless of whether the exercise was high or low intensity [cite: 17, 19, 20].

Furthermore, the drug diminished the patients' gains in aerobic fitness. "If you exercise and take metformin and your blood glucose does not go down, that's a problem," Dr. Malin reported. "People taking metformin also didn't gain fitness. That means their physical function isn't getting better and that could have long-term health risk" [cite: 17].

### The Biological Mechanism of Interference

The answer to *why* metformin sabotages exercise likely lies in the very cellular mechanism that makes it effective for diabetes in the first place: its impact on mitochondria [cite: 16]. 

Metformin works, in part, by inhibiting Complex I of the mitochondrial electron transport chain. This mild inhibition reduces oxidative stress, slightly lowers cellular ATP energy states, and triggers AMPK, essentially tricking the body into a state mimicking nutrient scarcity [cite: 4, 18]. In a highly sedentary, diabetic individual, this metabolic shift is beneficial. 

However, the physical adaptations triggered by exercise rely on acute bursts of mitochondrial stress and inflammation—a biological concept known as hormesis [cite: 18]. By artificially suppressing this mitochondrial activity, metformin prevents the necessary cellular adaptations required to build aerobic capacity, improve mitochondrial function, and enhance vascular health [cite: 18]. The drug effectively intercepts the stress signal before the body can adapt and grow stronger.

[image delta #1, 0 bytes]





For older adults taking metformin off-label specifically to improve their healthspan, this creates a profound clinical dilemma. If a patient relies on a daily walk, swimming, or resistance training to maintain functional independence, taking metformin might inadvertently stall their progress and limit their energy for daily life [cite: 17]. This has led experts, including AFAR's Dr. Barzilai, to caution that metformin is not an appropriate anti-aging biohack for younger, active individuals looking to build muscle or maximize fitness, and its use should likely be restricted to older populations exhibiting established hallmarks of metabolic decline [cite: 21].

## Federal Funding Steps In: ARPA-H and the VITAL-H Trial

While the TAME trial waits for philanthropy and debates the nuances of exercise biology, the U.S. federal government has bypassed the deadlock entirely. In February 2026, the Advanced Research Projects Agency for Health (ARPA-H)—a health-focused agency modeled after the military's high-risk, high-reward DARPA—announced a massive investment in longevity science [cite: 22]. 

Through its PROactive Solutions for Prolonging Resilience (PROSPR) program, ARPA-H distributed up to $144 million across seven research teams to fundamentally treat aging as a tractable biological process [cite: 8, 22, 23]. The agency explicitly acknowledged the flaws of the current clinical system, noting that the long, slow process of aging makes traditional clinical trials that wait decades for diseases to manifest far too unwieldy and unappealing for private investment [cite: 22, 24]. 

PROSPR aims to leverage longitudinal human datasets to identify early-responding biomarkers that can serve as surrogate endpoints, enabling clinical trials to assess intervention impact within one to three years instead of decades [cite: 23, 24]. 

### The VITAL-H Trial at UT San Antonio

The crown jewel of the PROSPR program is the Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) trial. Awarded up to $38 million, VITAL-H is being led by Dr. Elena Volpi at the Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio [cite: 25, 26, 27]. 

Positioned as the first nationwide, Phase 3 clinical trial targeting aging in healthy adults, VITAL-H sidesteps metformin entirely. Instead, it will enroll 726 generally healthy adults aged 60 to 65 and test three different FDA-approved medications head-to-head against a placebo over a three-year period (followed by a six-month washout phase) [cite: 26, 27, 28]. 

The three drugs were selected based on mounting preclinical evidence and promising human data regarding their ability to impact the biology of aging:

1. **Rapamycin:** An immunosuppressant originally used to prevent organ transplant rejection. In geroscience, it is considered the gold standard intervention. Rapamycin directly inhibits mTOR complex 1 (mTORC1), a cellular pathway central to cell growth and nutrient sensing [cite: 29]. Over the last decade, it has consistently demonstrated the ability to extend the lifespan of yeast, worms, flies, and mice, making it the most validated longevity target in animal models [cite: 25, 29].
2. **Dapagliflozin:** An SGLT2 inhibitor originally developed for diabetes. Dapagliflozin forces the kidneys to excrete excess glucose through urine. Beyond blood sugar control, these drugs have shown astonishing abilities to improve cardiac and renal function, while simultaneously lowering low-grade systemic inflammation (often called "inflammaging") [cite: 26, 30].
3. **Semaglutide:** A GLP-1 receptor agonist famous for its weight-loss applications (marketed as Wegovy and Ozempic). While controversial regarding its effects on muscle mass in older adults, semaglutide has shown massive benefits in reducing major adverse cardiovascular events and managing metabolic syndrome, addressing one of the core drivers of accelerated aging [cite: 30, 31, 32].

### Redefining the Endpoint: Intrinsic Capacity

VITAL-H also solves the regulatory puzzle in a slightly different manner than TAME. Rather than waiting for a participant to have a heart attack or develop cancer (TAME's time-to-first-event composite), VITAL-H focuses on validating a concept called "Intrinsic Capacity" [cite: 27, 33]. 

Intrinsic Capacity is a composite measure of an older adult's physical and mental functionality across five distinct domains: locomotion (mobility), cognition, psychological health, vitality, and sensory function [cite: 30, 33]. By using a decentralized, hybrid trial model—where participants take a daily pill, wear health-tracking rings for sleep and cardiovascular data, and perform regular assessments across local community sites—the researchers aim to prove to the FDA that preserving daily functional abilities is a meaningful, regulatory-grade endpoint [cite: 27]. 

If VITAL-H proves that rapamycin, dapagliflozin, or semaglutide can preserve these everyday abilities during the critical mid-life window, it will achieve exactly what TAME set out to do a decade ago, but in a fraction of the time [cite: 25].

### Comparing the Titans of Longevity Trials

To understand the current state of clinical aging research in 2026, it is essential to compare the stalled blueprint of TAME with the actively funded reality of VITAL-H.

| Feature | TAME (Targeting Aging with Metformin) | VITAL-H (Validation and Intervention Testing) |
| :--- | :--- | :--- |
| **Primary Drug(s)** | Metformin (Biguanide) | Rapamycin (mTORi), Dapagliflozin (SGLT2i), Semaglutide (GLP-1) |
| **Target Population** | 3,000 adults, ages 65–79 | 726 adults, ages 60–65 |
| **Primary Endpoint** | Composite disease onset (cancer, heart disease, dementia, mortality) | Intrinsic Capacity (locomotion, cognition, vitality, sensory function) |
| **Trial Duration** | 6 years | 3 years (plus 6 months follow-up) |
| **Coordinating Center** | Wake Forest University / AFAR | UT Health San Antonio (Barshop Institute) |
| **Estimated Cost** | ~$50 Million | Up to $38 Million |
| **Primary Funding** | Private Philanthropy (Currently Unfunded) | ARPA-H (U.S. Federal Government) |
| **Status in 2026** | Awaiting Recruitment / Stalled | Funded / Initiating Enrollment in 2027 |

*Table 1: A comparison of the trial structures, funding models, and clinical endpoints of the two most prominent clinical initiatives aimed at securing FDA validation for anti-aging therapies [cite: 3, 5, 8, 25, 26, 27, 28, 30].*

## Global Longevity Initiatives Surging Beyond Metformin

The shift away from a single-drug, metformin-centric approach is not limited to the United States. Recognizing the massive socioeconomic burden of an aging population, international governments have aggressively stepped into the longevity space in 2026.

### Singapore's "Grand Challenge"

In May 2026, the government of Singapore launched a massive S$350 million (US$273 million) "Grand Challenge on Maximising Healthy and Successful Longevity" [cite: 34, 35]. Aimed squarely at preventing cognitive decline and the loss of physical function (such as sarcopenic obesity and vascular dementia), the initiative is a cornerstone of Singapore’s Research, Innovation and Enterprise 2030 (RIE 2030) plan [cite: 34, 35]. 

Singapore faces a demographic cliff, with 1 in 4 citizens expected to be 65 or older by 2030 [cite: 34]. To combat this, Health Minister Ong Ye Kung is encouraging public-private partnerships. The program allows multinational biotechnology firms to access the nation's highly coveted anonymized health data platform (TRUST)—which aggregates data from nearly 50 health datasets—to fast-track the testing and validation of longevity innovations in real-world clinical settings, with intellectual property co-owned by public and private players [cite: 34, 35]. 

### The European Innovation Council's 2026 Pathfinder 

Concurrently, the European Innovation Council (EIC) unveiled its 2026 Pathfinder Challenges, dedicating a significant portion of its €96 million budget to "Biotechnology for Healthy Ageing" [cite: 36, 37, 38]. The EIC explicitly noted that society must move away from addressing age-related conditions individually. The initiative funds high-risk, early-stage biotechnology that aims to prevent, delay, or reverse the onset of age-related diseases [cite: 36, 39]. Rather than just testing existing drugs, the EIC is demanding the development of novel biomarker-based tools and New Approach Methodologies (NAMs) to measure biological aging safely and capture its systemic nature [cite: 36, 37].

### Private Markets: Patented GLP-1s and Epigenetic Reprogramming

The regulatory logjam that TAME struggled with is also cracking from private industry pressure. In 2026, Eli Lilly entered negotiations with the FDA to run a TAME-like composite endpoint trial utilizing a GLP-1 agonist [cite: 8]. Because GLP-1 drugs are heavily patented and immensely profitable, pharmaceutical giants have the financial incentive to fund the massive trials required to prove they extend overall healthspan, solving the funding problem that TAME could not [cite: 8].

Simultaneously, the bleeding edge of geroscience has moved toward cellular rejuvenation and clearing damaged tissue. In April 2026, Boston-based Life Biosciences initiated the first human trial for partial cellular reprogramming using Yamanaka factors (OSK) delivered directly to the eye via gene therapy [cite: 6]. The trial specifically targets glaucoma and sudden vision loss (NAION), representing a landmark event for true epigenetic age *reversal*, rather than merely slowing decline [cite: 6]. 

Trials investigating senolytics—compounds that selectively destroy toxic, "zombie" senescent cells that drive tissue inflammation—are also proliferating globally. Trials assessing the flavonoid fisetin for multimorbidity and frailty are ongoing across multiple sites, while a Phase 2 trial in China (COIS-01) is actively testing the combination of the senolytics dasatinib and quercetin alongside immunotherapy for head and neck cancer [cite: 6]. 

## The Future of Metformin in Personalized Longevity

Given the rise of potent alternatives like GLP-1 agonists, the advent of cellular reprogramming, and the complications regarding exercise blunting, is metformin a dead end for longevity?

Not necessarily. Rather than serving as a universal anti-aging panacea added to the water supply, the future of metformin in geroscience will likely rely on precision medicine and pharmacogenomics. Recent reviews published in early 2026 emphasize that physiological responses to metformin vary wildly across aging populations based on individual genetics and epigenetics [cite: 4, 11]. 

Specific genetic variants in drug transporter genes, such as SLC22A1 (which encodes the OCT1 transporter), dramatically affect how metformin is absorbed, distributed, and cleared by the body [cite: 11]. Furthermore, polymorphisms in metabolic regulators like ATM, LKB1, and PRKAB2 dictate how effectively a patient's downstream mTOR and AMPK pathways will respond to the drug [cite: 11]. Metformin has also been shown to influence epigenetic modifications, downregulating aging-associated microRNAs (such as miR-34a) to preserve cellular homeostasis [cite: 11].

In the future, clinicians will likely use epigenetic profiling and genetic screening to identify specific sub-populations—perhaps older, sedentary individuals with high inflammatory markers, central obesity, and specific OCT1 variants—who will derive immense healthspan benefits from metformin [cite: 11, 40]. Conversely, they will advise active, athletic individuals to avoid it to prevent exercise interference [cite: 18]. 

Small-scale trials are already leaning into this highly targeted approach. For example, an ongoing study at the Queen Elizabeth Hospital in Birmingham, UK, is administering metformin alongside fisetin and spermidine to 60 adults over the age of 70. By extensively characterizing participants through blood, adipose tissue, and stool samples, researchers aim to map exactly which physiological levers the drug pulls regarding cellular senescence, autophagy, and epigenetic age [cite: 41]. 

## Bottom line

As of mid-2026, the Targeting Aging with Metformin (TAME) trial remains officially stalled by a lack of commercial funding, stranding its brilliant regulatory framework in an endless waiting period. While metformin's status as a universal longevity drug has been heavily complicated by new clinical evidence showing it blunts the cardiovascular and aerobic benefits of exercise, it remains a vital tool for targeted metabolic control in precision medicine. Ultimately, the field of clinical longevity has evolved rapidly beyond TAME; federally funded mega-trials like VITAL-H and massive international initiatives in Singapore and Europe are now taking the baton, utilizing billions in public funding to test superior compounds and novel biomarkers to fundamentally redefine how humanity treats the aging process.

**Sources:**
1. [hevolution.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE9-5WHIRQWqgAeWlRfYPWgAvYZJsCC3c2mTlni201HamlX35JbkR7NCTYzAm1HWvApHmCzKr9orCQV8LRNJsH3iQ_wHCYjCdSHlAx2)
2. [ghs2025.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrIZlR5FGsMl7RZbv_upXEY35FZedY4XdC12VKM5jBa4Qfv727CYAxZfUwlK15YcY4kMuKBn-xp6kywGK0Y99D1j625W4aWxmAsCK9_lOeMvl7NfGi6QqiSQ2TS-21IuM=)
3. [clinicalleader.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFvTyD2Ay3B-fHTaymp5q1qrjQm_VnXqo3ycevjLKnTwgB9BBX_BDvpy3BpRrO-aNDr7wifwF3HTTOUAIzpVKIPz9t6-9n_dNeNSGXNkPDsFMHjIYVyYa8bYzkqyYIAiRpB15NQVmNGWTZguYAoLUVsAyuhPsgmhNv3qGxs4bsuezIVAv2Sgdt26QLoVszDg7WaYrs01YVSytbW4_DDF_rNLcWCpmAWYupiDE2AJB6Jg-FDzO3xtzK_yyM=)
4. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEdfxJziBlXrZUwwpRTXemAry-vCWMSyHBo3LlKjeJBuWXpWsyYHtXt4hdF61w6W9dPUxy3YNMdsKt1hZVGjzXnr8XMPIru9dxxfch_PrxQF-FKsHHlFsNcno1TnUZ8ue7_TMy1cOed2nMKdzGFMzx2hdJGSbQj1NO7R2Y2phsgHTd-KiemYuJm1CPE0kAuSUcET97Cfot1RTBhDySLKyHoRwJUryOR1Z-L56muN3Qx30uJK9WNRM9w4KPQGTHsyw==)
5. [afar.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHi_MgI5hWBYfjU-_bP2MHUo-n3FUKgINW-tvGjQz2Zn22aewGtcP2E8Kskk2qhfLzwZ1SIPZeOEJaF2IXbPiD9CLPat5Ly0AFLa0Ed-uBXqJvNfYk=)
6. [globalnewworld.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGhtXCDjRDYb7-LmudnGgVKPdp7bI_xdDEZI0UrFRemjUt3deBd-8UH-ciN0iWM8kd2EAo2bR8bklwqvMDXirPt42Gzwc0t7miqnhFeZnoFQ4CBtzvZFn9H4lsNNjPhz0N8PZOqwgdva8T-PpIyGfrvfveb9A==)
7. [afar.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjXZBxFoew9IUwwUPYyWPkWo9glLzEnF5dJEnwSxCccEM3by06Z-7wzCWQyg3P6MDYma2kzRsDbDQJMvtXfAwtlC6XQx6-fCPZLny2w6nGkprPOtOg9rOL73QewXSI2kYw2UDfsIA0knxsw7esc5RzsOMltpDoEhJqevqsbdliLabkFeh6IG-82XxHHtCBqr7ajjeuXCVFjYSV4pRjEubccP9S)
8. [effectivealtruism.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEFrfF1K-QT2b5HGzPfOSr0hytRU4NA5AdS_YMVCCD5Zk77IHRwVREK1FQt_D9282H6s7NwGb7YE1x0xfNOH6dygTsLvWBBNF48Yewp6K4kKVNx52cPap1lbjCcE17ueyz2wEhwjK-BsuCmjyOJMRO8FSYeRW2t3jLdeZMo0LO65WjNcq0fVTOsdm6i8YOcrqRKAh8PR20d_ocK3S6f6msOhy4a)
9. [preprints.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFbAW9C2PWv_HkOa80q5-qq0ZluekPJu-8DU5gB2kTovjVMIsCfOsUjX5YBgLO2odPvW6w6dpxInqQCL4uN8MksDvjSfI2o5isdkidc-lyod3K__WkfAwfqNiG1Cytb_yi-hM2bnw==)
10. [bocsci.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuJcO2MioigWEajTvEsL8ZXQ5GMFfcR29H_blnEIKlvPJ1NCi4Wd9zbgzfnwoA-BeoQA3Xtdi1H0D1ywBrGfNboTqpwSzjP96ktgv5taNcVVemb-T0xQquLRcSeqUBAsoqD4L2RBEUkhbWshLhTNISylBOQA9ibRMd-Q5i0xNoDEvQljKSUN6c5nY_k7UmpPhT)
11. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGuftX9LZkr-pEDRVATnH7-zPF5pf-fWZUJTzk4z8bSk9Z-kui_OcT-Be4Y57UMA4apDeqaIMUXQTLeJGzQ0ftne5AgNLiqvnaNyTg0AdvThDDqTkUZNJOPw0DtzoHPB8ZYFID_Bv0nKIDdbT_zo3HZnCrYNBkxuZlwpYUlaxzcQg5J7bsmJmIUadsCMLGposWMJ26z8RkAUbpbiVs_DuIyNzcxlLiG9f6yNRxIR99-Eq5Xlha-rBHD8Axc-0iw_W6nt4Nc3pA_o-TZDPZ1U561aNUcyMEP4dY=)
12. [goodrx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEjh-Db-b0OrFX0d5bBvgvWR_uJ8TfZ6HAvtUG1eTUZHMVoBwWqLgsqg2hEayKdp1rrx1Nenawzkev3SDuOElFwqqFfBH4ffhkZ9i6znjRJsWUaQMsC7XU7FdOcsRg5YX8=)
13. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7nDaquOGdlHS0RaZpCbgXByC1Dj4KuHbamzY0LlnVYZdjgiwjZa14qNJG1rGwGZNyC4wzsZgxpm_yfKrEqF1-dr-6fCSWjVTOJLmHcBQs2xRTFh_wT2aePcnjgT_8U-sAama2RXHO4Q==)
14. [grantedai.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGyweOBOyrdzAchAoT-peJBvxD69wRBFZK-10pyBaWWfZmv_QmUYA0J6VmqTjx3OJgECMDyJambuxDRdhQ273trgAcqQ2HmTV1itbEDGHCP5a11jxSiOA71yfLnanC1IBs5P2h2d272Hyt8GQetZ-hl8GEK2TxtyUoBWAJnDfor8NTUbjOLlg3JWmmgG_GMdJgaJBg-SZ3EtEMlWME=)
15. [hevolution.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHiVQvV-mSk07yk_PbPTDjdcE6YdyWBFv3qUT3o_-5VI2iI-OolbpQHaLWQmBrwS6kNU387-1NTMyIEtu7HV9wDt3KZjJYjZ_MVJNdwgSR3DuAEyfjqr0sb5n0lEvq4lVU1QFYDHe8uuhYuYqQRuEj9BQnsygPXrjUm2d8=)
16. [sciencedaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8HJAMPaSMHYVehLaU_RSzp2blXeRan3hV4S20htFjD5cb1lcpbVv9PXjHD2YffgnNdhOBLUuHxrmD78c0DF5T3nnjBDPx8xGnUli_WNArGGUdNDAeUPTV1DD7EyqJTU8ZzwKEggOFgWWCEm6DSQmubq2t)
17. [scitechdaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEpwX4wRfxPZwURc4VJ4xgPQ8nakc0k6sYSRQKtQ9RFuRsF_5k6CeZ2GpCsyouRfLul4jU5xDPtXG40v3UoQ7h08rba35rbjGrKF0ZkSz-9pGKKcVj4canZnNlAA93RaGXDOXSszSlzeDGO1TzIfb5oEFdLG2WCdErFLT0x7RWGr357PJ-5Imf68TvYRoyXrGOYPBS4lZwu7VhsQg==)
18. [rutgers.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGSW48S6tSp0m5XcjnA2Spmk5vV0Qup7sRUcHsTZTX7wZPbePRRAeMymJpK-L6xbBvQmrZvxs0EpN7Gm7YuDUdkHKGOkR_6i6-nMTjIlypy6VDtaR1b5Kmremq-fnMxC-UBcGAabu4A-IDt5_txAUCa306NibsSLflkNppOJ8lqEpCaPnHF0tyUpDkOZg==)
19. [uspharmacist.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHiEKpmeDhBedLWPTzBwx3Q2aFMf41KOc0Xn3ItQCn_EukIc0hJnBC3aGzXYKjDJLEvqASUjizyfgrR9lHt1DzKpqyQxWMdySeI65iVlapST4A_OoQRC5biXnNC4A-6ud9rN3N5ndsiMJVMg8BQD0sx27x6AuWKSBWdzeis2AlN-iwdgG8xZjm54HyU3I=)
20. [news-medical.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFbkAlFM7R10N8Ido4E4oiO66Oa5KQm9RjCeT5D5D4z3mzavnUQeK1kuwq2yHQ0rhQqh5dORBJXJPIF2_av71IIukCA2r7a3zthXyKIhMC6oLJlwYNGQGeFbGaR0c19QFOQ7nvj1LSCiv14hJ0u6LL-ezWWuqls4HPDeYD8z0kwWOG1J6oqRJi5TOUjzHdpuhB5opHghLUV_Tj3jOkmHw==)
21. [afar.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGgQ7V6WjL6PFuEN9F_Mi_K8FjaW5vOPRHyNLKI7VzfMcJp2wjSyTV4kRZZXix096IHK7rLF11NCWuCSriv3mWB7lykcpGAspiAok8S2Bv7pqgNgIC-bt9e0900i5WJO5RY1b6QfOAgWs1fwLgt_xeAVTcBcO9X-s_c3VCk7jozAEnq-XBQTaRSECjaSADtM9RNpxh4kuq6TEf78s-jA_gc_uUr)
22. [arpa-h.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEP-xsXUVHeby1dKcDrHQv5oO31e3Thw97HEi_Rl-GMh37I5xTpxU3mQ_ahTjulWKoImhNzGDLjasHHmCLVygc3dPD7SWCt6mT-VTV_elM7DsjTx1xpdXEORyEtLnwKCqwvNYFTMW6Il-8JR4ZNcuDRewdEc92jZHJpnWWZSAQfmXskNhwGc6Ma65kD7vPSi5v3hClwVUU=)
23. [allsci.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBS4oAkPPPYicdRDSH7vplCpsds2HCvq6XBXY-hhmEW8uY8UqjWmjEasdXOpgNX0KS4pCRJhUsK0LkhKY9ChXIQnBnE_cySYIORFhZNqWlDlbxDZ2j8z9rMHII_WmSZY3mZwzEv7GFn-tTJn655nYRfXW23pwrInVykVUkoLGWb7Yowcy0ezO_f-_kOmOrH_GsDk4VUW_cWdLPTAY=)
24. [longevity.technology](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfF74wGRPdCDg9WjMY4dsKLCavq4Iyv5gsSeZWitSBVIlQGZtErvdoCGsRoIOdfCmTeV4AhYoJUwYza1t-WJaMyUtX22ZJjXok-dH6SyFubWexX-Ce8ByNsrib_YwG8WMKTVEQkK1WA_cFrzTatc86K317cGQEucBQ-lb10DWzpggBKjpiwr-C5uGntFZfBkmznA==)
25. [uthscsa.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEm33VNTSYX2hDiepdpcwTqvRjCgB86yZADzh4-MBXU_kdF8TynkFQW5h0zvxaOTvZoiRTXR-3zo1ESsddyF51ymw5Eef332KPAvWADttV1yXgAI9m5DnuShlaJB6iydlGbpauLLYYOX8vzaYht1jfGfvtD3h7hr2Ux3aGltW3tShfMMq1_JVitWlmN7ezuUIMYa6hLS8QYt1kV_QDdnwo9tN7ddJPQ2AejuL7ZA1mub0QA-y231OPJKpM1po0L5yelAY8F2VMs6s3JwjCziM4Vx6G6sSzLuTMUkKP_OAAxm6G1uRqhnVmEBHPh1vpvnTZ8xZN8zA==)
26. [sanantonioreport.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEafA5Cjd99A7K9S6yAnCl4DTVRtEC74w-oyj-tv6Tm0pKcwyYKNMUKNek7P6DCA36xuITYR3QIsTri0wWTAVQuqye0iVBKICytWGGiHoSd8PKLU6fTE_ibIvdpye006o25_YdAxDO084oYecITiRmUYl5TUU3lMUgq9mGcfJwl)
27. [uthscsa.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF1k6pzBtQ99JsYLLT_FSyG-A5QZVU64XUcEItgBo67sLQcHtLH8NWdWiPnjrCih9-ZYpSkLPf4c640JvGGhEOk2QYk2Yo_E-zpjLhF0GUX6grBEJkEKYS-oP9nQ6CzEvrgLR5hDXm67mGwQT4A9yVkk544LgoefgWG88aqoEoEZZR-gffXGAgPoNdJDEV8z2W2lF9IYI2tQruIdAhaRLDunaU=)
28. [tpr.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJ2Jqrv04Aq0ylNdO86tudivTFdb3ocVADb_IemzgXvMQIqXdesq6_fzJuX8d-Ps33gYbs2qijhVxHNfuZqdfDSzvsFFVQq8VUR0mOGib37XLtnVlThk2FP7hqePfXkU3doYTBiPGH78-PGV3n1IFTcrVkzfy4eYcMWtT6v-07-A9uVoRSw4IBLPDGx2GiIxLVMICRIfQrc1DkE4Yw7X9dGEe8hBm5yv8NIh43xAUOX8szdf0=)
29. [substack.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHxLMhpTEGm-YK018cbleHT5P6jboiu93FEXB1NQDpwJ3oke1-m38NVGYopBPn6t-KucMSDbFLgY3D67MK1-aSvVasrRo3Tdkw0xqIbAJ0vS1ixNFwiV-z1-dgmDwQVAJgEfKtmsn55xUfGpkqMPvo47FxvJnZais4=)
30. [aamc.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE5aUkXBkA9Lp_RUklCsZ1hCxxzvz6b48TIbwW9giTySCGt_QmeHa5enMh9CzB05he1XQdN7U_J_eoRZedPkKAqAEMYVhEbBy2YbNTw9LLQLv7RTjTAa9J9_8WGN39KZJFI5C2q8wKe1y6a3QcnlaoZIHNGdJR6miW8MosxsyTYNc3aPYw=)
31. [themetabolicclinic.com.sg](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGR9TRP-eQ3OY8c1TJhlPbj9Djld_-6YBIch1J7SiWtz4jDnUiEuARM54esSYkARJILJGdsGeLqxfEkEuLLXO7mSzCjYgds__Q9d-KWZBS533q2wyF4F0G3mfD1uIi-CuBpE5sTP0yCm99wQ==)
32. [techlifesci.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRRGtw6q-GCJOCY9yaPn9uGvY8RZ_jq4wa92WsL4pCoOBb8wgoV0AQXM2W7pICkzNthsU_gMVzHhirv3vhMkHTPKMtMO6vVAHfBkosVp1mH_f4180lhA7ArmQ_OgFV2OR8iWtEUXBCNoCXAmboP4v6)
33. [uthscsa.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH3J8Go6nwcjvt3LsvQG0hlkprd-RhI_ahwb2tc8eTT1SBt9tV8SFhFIzv0Kx6pdg7GEcvK4padtYxuVe76EJlShWCO2frpkSeqt2T44pzmw6BS3_z8LUOKCEcy_X3FrzwLOOuC-hUtihX2jKvW2hsgAa7Kjyzw5CWvxrzmUdOuMaTAwzRMXY2Xue0mjxtR3syeaPmmcUJl8rI-_KP4lv6cpBCEpjz2aqSvtPar_96r1cIdxqVVLmFfzpORcYhrJI9cAxmooHRk2KiKhkE3epcMfYj8MdDmvuX20c51xPE=)
34. [nutraingredients.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGs-dr_wz7UX1kri6sE8pzFswWUNwTaQqyz7BmBRL4K4AlyE8lMVNwOIPVooh5fTB8TjxoZ_GpwNfjWdZDv4Ws7dvXfBTHv5WNF9dy31w2DeKtFXTcnzFVbT1De73hQCJ79KDjMt4MUumSR9qkSPAerzu2qJ3fqAZfMcYfIIp7KUnGqUNXGu7aJtjj1jNbUgsXaO59qE5cpUCqPIFtKvA==)
35. [straitstimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6WjWD5zjoYlgON1K5CeOLdApRzGyU9OLac9nIQrG82JE-5dbiNV3oDv7NnHWMyQmT3XwRXaIOa6S-JpVACqi8dpM2roBj81GhV1q068MFUIUlcbmG1UeIzgOxf7yaDR023QYQYKM3-qs93RUqE5IZqUyU5FU7APym7Az6nyGWgw1_-yelrCJ2-JR8gsgLdhE76DY7oVfOTTJQ9wHtlZKKpoyTt2q08paVz8j6Ko7hbvxlOlK0D92Yuh0HQyihPRzwHSLWng==)
36. [hezelburcht.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSW3HsB_OwquJga5TFsVMAL9k0Gj544moO6eOdR6oiBU3o9noosiSbew-O-m2-VmciwsCCSdoySF8R7Op3CqxZclRmihzVgJBHqXOtcAmA5dmV_hp5gGAHN6CDGuzfnGboerJ5DrEaz26ru-McrPNT-xKAiS6f5_lrpWgJO1-wKgOZ08KW_EmJS8szckr0lCg2vrGGXc3HvQk=)
37. [spinverse.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFEoDkDfebvxIb-l-nISRmurYTOEuR9qjlFIV8cq28aT0JWiQ3OmX5sj3YmZjh359_vh4MlHLPZAQV14Z5WSR2j5VjD6DdAA1MHC9J7sJul1KLKKNNeHyozP4829H-xbyHavrTE_h94TY2-3N1t6eURtWQO4yx-t75haBh7ufcBQYEWd-BYOLSP0U6NoA==)
38. [europa.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEdim8gaTJ_MITWllkHc0sil6883OEFZJKK-DtBZTq5JnCnTGvUn6a7_Uwehd8G3ezXnYla96B5RHJMLX1HV22pzzj6cObmHuy34QxBGBwLFSMsA5pvSRsJUchX_kSd422pe1h54ZPYeMxy4B0FV6aB0NDEdfeEbQta)
39. [europa.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFlb9EuUdFc7RER3E3aKJ4a0t7FvP-x9xL5_Omocy1Pt77OW5oyM-DsTT-bzt5217hTh4eFJsYPgsWpLBM6SyypkPxuBp4v1rpbL1svzGiiNJEiFr1FwWMrBvBKn8bA-a_jnnyqnOeSCQ1iUslymGNXKI4LHfcj1QY6uPsQ2RsfHyRzwnwDuLoUW48UWIpIF6VZWicODKbjLQ==)
40. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGzOkIWWgSIIi5_ggZmtW0QcMfuxwewj2Pm6RrldLHRbt8ZRCojZpkdsjGZ6HgVaIHLUSPuz8n9H8vlCvJ-TX4LCEKK0canQDw2LSQjJjqKQ3y7cAmka8JvUplrh7YyvlGP2gR1vGQgWeqAwfT2EDF7j1jnglPDHMR6VuzWN35Iwbogq-SUz9UYLRT9NqjlJ9z-gxzh5V7t9QLzMt1KumgLuarCs8Ci_HPztarL3Vqfw0gxAsFESm-UVs42HgUvVipv1PH1ECxd79AXgrlyypvG)
41. [medrxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSrCZSiN-b4YSPGgierUX8eZv1qufEFfpLIqrw_AbeQYghL_oRdpL3BwK5CyEcpTWbPwuODF8svABGKaLybAgudbk066fOXY3mtJM7NpGEePy84RFBHjKoFMNMm1XpdIDeotqSUAvPTw4mTEe5ZyX3V-FUAizSfkTDziJfnQ==)